Chromium and polyphenols from cinnamon improve insulin sensitivity

Richard A. Anderson
Beltsville Human Nutrition Research Center, USDA, Beltsville, MD 20705, USA

Naturally-occurring compounds that have been shown to improve insulin sensitivity include Cr and polyphenols found in cinnamon (Cinnamomum cassia). These compounds also have similar effects on insulin signalling and glucose control. The signs of Cr deficiency are similar to those for the metabolic syndrome and supplemental Cr has been shown to improve all these signs in human subjects. In a double-blind placebo-controlled study it has been demonstrated that glucose, insulin, cholesterol and HbA1c are all improved in patients with type 2 diabetes following Cr supplementation. It has also been shown that cinnamon polyphenols improve insulin sensitivity in in vitro, animal and human studies. Cinnamon reduces mean fasting serum glucose (18–29%), TAG (23–30%), total cholesterol (12–26%) and LDL-cholesterol (7–27%) in subjects with type 2 diabetes after 40 d of daily consumption of 1–6 g cinnamon. Subjects with the metabolic syndrome who consume an aqueous extract of cinnamon have been shown to have improved fasting blood glucose, systolic blood pressure, percentage body fat and increased lean body mass compared with the placebo group. Studies utilizing an aqueous extract of cinnamon, high in type A polyphenols, have also demonstrated improvements in fasting glucose, glucose tolerance and insulin sensitivity in women with insulin resistance associated with the polycystic ovary syndrome. For both supplemental Cr and cinnamon not all studies have reported beneficial effects and the responses are related to the duration of the study, form of Cr or cinnamon used and the extent of obesity and glucose intolerance of the subjects.

Chromium: Cinnamon polyphenols: Insulin sensitivity: Metabolic syndrome

Decreased insulin sensitivity or insulin resistance is associated with the signs and symptoms of the metabolic syndrome including increased visceral obesity, fasting glucose, elevated TAG, decreased HDL and hypertension. The metabolic syndrome is often a precursor of diabetes and CVD. Factors that improve insulin sensitivity usually lead to improvements in risk factors associated with the metabolic syndrome, diabetes and CVD. According to the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) criteria(1), individuals with three or more of the following have the metabolic syndrome: fasting plasma glucose level of $>6.1 \text{ mmol/l (1100 mg/l)}$, TAG $\geq 1.69 \text{ mmol/l (1500 mg/l)}$, HDL-cholesterol $<1.04 \text{ mmol/l (400 mg/l)}$ for men and $<1.29 \text{ mmol/l (500 g/l)}$ for women, blood pressure $\geq 130/85 \text{ mm Hg}$ and waist circumference $>1.02 \text{ m for men and } >0.88 \text{ m for women}$. The incidence of the metabolic syndrome varies from $<20\%$ among the Chinese and Korean populations to $>50\%$ among Maori and Pacific Islanders in New Zealand$^{23}$. Approximately one in four Americans has the metabolic syndrome. It is progressive and often culminates with type 2 diabetes, which increases the incidence of CVD. In patients with the metabolic syndrome the relative risk for atherosclerotic CVD ranges from 1:5 to 3:0 depending on the stage of progression. The risk for developing diabetes is fivefold higher for individuals with the metabolic syndrome compared with those without the syndrome$^{3}$. Since the metabolic syndrome is multi-factorial, strategies for reducing the incidence and consequences of metabolic syndrome must also be multi-factorial, and

Abbreviation: CP, cinnamon polyphenols.
Corresponding author: Dr Richard Anderson, fax +1 301 504 9062, email Richard.anderson@ars.usda.gov
Chromium decreases visceral fat, subcutaneous fat and total fat. Thirty-seven subjects with type 2 diabetes were placed on sulfonylurea medication for 3 months followed by 6 months of either 1000μg chromium as chromium picolinate/d or placebo. After chromium supplementation body weight, glucose, insulin and NEFA were lower than for the placebo group. Mean values were significantly different from those for the placebo: *P<0.05, **P<0.01. (Adapted from Martin et al.(10).)

Chromium

The signs and symptoms of Cr deficiency are the same as those for the metabolic syndrome, i.e. elevated fasting glucose, elevated TAG, low HDL, hypertension and visceral obesity. The hallmark sign of Cr deficiency is impaired glucose tolerance and there have been numerous reports of beneficial effects on individuals with impaired glucose tolerance and type 2 diabetes (4–6). In a study involving 155 subjects with type 2 diabetes a dose response to Cr has been reported for fasting glucose, postprandial glucose, fasting insulin, postprandial insulin, cholesterol and Hb A1c (7). Similar results have been reported by other research groups (8,9).

A key to controlling the metabolic syndrome is to prevent or alleviate visceral obesity (3). A recent well-controlled study has demonstrated that weight gain in subjects with type 2 diabetes is clearly regulated by supplemenatal Cr (10). Thirty-seven subjects with type 2 diabetes were placed on sulfonylurea drugs to control blood sugar for 3 months and then randomized to receive either Cr or placebo. Subjects receiving the supplemental Cr were found to have smaller increases in body weight, percentage body fat and total abdominal fat compared with those in the placebo group. Subjects receiving Cr were also shown to have increased insulin sensitivity, corrected for fat-free mass, and decreased NEFA (Fig. 1) (10).

In a study involving twenty male and twenty female swimmers receiving 400μg Cr as chromium picolinate/d, Cr was found to significantly increase lean body mass (3.3%), decrease fat mass (−4.6%) and decrease percentage body fat (−6.4%) compared with the placebo group (11). Females were found to have a greater change for percentage body fat compared with males (−8.2 and −4.7% respectively). Effects were not significant after 12 weeks but became significant only after 24 weeks. This study supports the concept that studies involving Cr supplementation and lean body mass should be longer than 12 weeks and should involve ≥400μg supplemental Cr/d (12).

Cr also decreases cortisol concentration in human subjects (13), which is important in relation to weight control because cortisol increases circulating insulin and increases fat accumulation (14). Adrenalectomy of obese rats leads to a normalizing of insulin and decreased fat accumulation, and after glucocorticoid administration there is a return to elevated insulin levels and accumulation of fat (15).

Studies involving improved lean body mass as a result of supplemental Cr in human subjects are supported by animal studies conducted mainly using pigs; Cr increases longissimus muscle area and decreases percentage fat in pigs (16–18). Following the original studies showing beneficial effects of Cr on lean body mass, pig producers started adding Cr to the feed of sows, which would also affect the Cr status of the young pigs (19). Goats fed a high-refined-carbohydrate low-Cr diet also have increased feed consumption and corresponding weight gain compared with animals consuming the same diet with added Cr (20). The increases in weight gain are attributed to the antilipolytic effects of increased insulin leading to accumulation of TAG in the adipose tissue. Elevated insulin levels in the animals receiving the low-Cr diet would also lead to decreased glucagon. As glucagon stimulates lipolysis, decreased glucagon may lead to decreased lipolysis and subsequent accumulation of body fat and weight gain. There were no effects until after 28 weeks on the low-Cr diet of low nutritional quality (20). If it takes >28 weeks to detect significant changes in body weight in rapidly-growing goats, it is not surprising that most of the human studies, which are usually ≤12 weeks in duration, are also unable to detect significant changes in individuals consuming conventional diets.

A meta-analysis of several human studies has reported that there is a significant reduction in body weight caused by Cr, but it states that ‘a body weight reduction of 1.1 to 1.2 kg during an intervention period of 10 to 13 weeks (i.e. 0.08 to 0.1 kg/week) seems too small to be clinically meaningful’ (21). Improvements in this range, if sustained, could lead to a loss, or prevention of gain, of approximately 4 kg/year, which certainly could lead to large changes over time. Even if Cr only prevents the increase in body weight of 0.5–1 kg/year, it becomes consequential with time. Improvements in insulin-related variables that affect body weight and lean body mass are a result of changes in metabolism and should not be confused with those associated with changes in dietary intake and energy expenditure. Lasting changes in insulin sensitivity and changes in metabolism could lead to lasting changes in body weight and composition. Additional long-term studies in this area are needed.

Increased insulin resistance also leads to an increased incidence of CVD (15). It has been shown that improvements
in risk factors associated with the metabolic syndrome also lead to improvements in heart function (Fig. 2)(22). Sixty patients with type 2 diabetes were randomly assigned to two groups and one group was given 1000 µg Cr/d and the other the placebo. After 3 months, QT interval (a measure of the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle) corrected for heart rate (QTc interval) was found to be decreased. The rate-corrected QT interval is a powerful predictor of total mortality, cardiac death and future stroke in patients with type 2 diabetes mellitus, and is inversely related to insulin sensitivity. BMI was found to be the only predictor of total mortality, cardiac death and future stroke involving sixty subjects with type 2 diabetes (thirty males and thirty females) who were taking sulfonylurea drugs(32). The subjects were divided randomly into six groups. Groups 1, 2 and 3 received 1, 3, or 6 g cinnamon/d for 40 d. From day 40 to day 60 there was a washout period in which subjects did not receive capsules. Groups 4, 5 and 6 received the same number of placebo capsules as the corresponding cinnamon groups. After 40 d all three levels of cinnamon were found to have reduced mean fasting serum glucose (18–29%; three groups, each of ten subjects), TAG (23–30%), total cholesterol (12–26%) and LDL-cholesterol (7–27%).Values after the 20 d washout period were returning to baseline but were still lower than the values at the onset of the study. In a separate study involving twenty-two subjects with the metabolic syndrome, subjects were divided into two groups and given daily either 500 mg commercially-available aqueous extract of cinnamon (Cinnulin PF®; Integrity Nutraceuticals, Sarasota, FL, USA) or a placebo for 12 weeks. Subjects in...
the group receiving the capsules containing the aqueous extract of cinnamon were reported to display decreases in fasting blood glucose (−8.4%) and systolic blood pressure (−3.8%) and increases in lean mass (+1.1%) compared with the placebo group. There were also significant decreases in body fat (−0.7%) in the cinnamon-treatment group (33).

Oxidative stress, which is increased in obesity, plays an important role in the development of diabetes and CVD in obese individuals (34). Hyperglycaemia causes the auto-oxidation of glucose, glycation of proteins and the activation of polyol metabolism (35). Cinnamon has been reported to improve the antioxidant status of subjects with the metabolic syndrome (36). Plasma malondialdehyde levels were found to be reduced by the aqueous extract of cinnamon, indicating decreased lipid peroxidation, while plasma SH groups were increased, indicating a protection of antioxidant SH groups against oxidation. In parallel, the ferric-reducing ability power, which is a measure of the total antioxidant capacity of plasma, was shown to be increased, thereby providing a contributory factor to the protective effects of cinnamon supplementation (36).

Polycystic ovary syndrome is one of the most common endocrinopathies among women of child-bearing age, affecting 5–10% of the population (37). Insulin resistance and the compensatory hyperinsulinaemia are present in 50–70% of the women with polycystic ovary syndrome and maybe as high as 95% in overweight women. Excess insulin secretion may also be implicated in the increased metabolic and cardiovascular risks reported in this disorder. Since insulin-sensitizing agents such as Cr (38) and troglitazone (39) have been shown to be beneficial in the treatment of polycystic ovary syndrome, it has been postulated that the insulin-potentiating water-soluble polyphenolic compounds found in cinnamon may also be beneficial for women with polycystic ovary syndrome (37).

During an 8-week treatment period oral cinnamon extract (500 mg/d) was shown to reduce fasting glucose as well as insulin resistance, with oral glucose tolerance tests also showing a 21% reduction in mean glucose and an increase in Matsuda’s insulin sensitivity index (40). The cinnamon extract was found to improve insulin resistance of the

---

**Fig. 3.** A model of actions of cinnamon polyphenols (CP) in the insulin signal transduction pathway leading to beneficial effects in subjects with glucose intolerance or type 2 diabetes: (1) CP activate insulin receptors (IR) by increasing their tyrosine phosphorylation activity and by decreasing phosphatase activity that inactivates the receptor; (2) CP increase the amount of insulin receptor-β and GLUT4 proteins; (3) CP increase glycogen synthase activity and glycogen accumulation; (4) CP decrease glycogen synthetase (GS) kinase-3 β (GSK3β) activity; (5) CP increase the amount of tristetraprolin (TTP) protein; (6) CP may increase the activity of TTP by decreasing its phosphorylation through inhibition of GSK3β activity. IRS, insulin receptor substrate; PI3K, 1-phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PTP-1, protein tyrosine phosphatase-1; PDK1, phosphatidylinositol-dependent protein kinase 1; FAT, fat; G-6-P, glucose 6-phosphate; PKB, protein kinase B; UDPG, uridine diphosphoglucose; GM-CSF, granulocyte–macrophage colony-stimulating factor; Cox2, cyclooxygenase-2; VEGF, vascular endothelial growth factor; −, negative effect; +, positive effect. (From Cao et al. (43).)
women with polycystic ovary syndrome compared with the control women.

The beneficial effects of cinnamon were greater in the study of Khan et al. than those observed in the studies of Ziegenfuss et al. and Wang et al. but the subject populations were very different. Subjects in the Khan et al. study had type 2 diabetes and were taking sulfonylurea drugs that increase insulin secretion. Since compounds found in cinnamon increase insulin sensitivity, they are likely to have larger effects in subjects taking sulfonylurea drugs. Insulin resistance would also be larger in subjects with type 2 diabetes than in subjects who are still prediabetic. The duration of the supplementation is also important to consider, since in the studies of Ziegenfuss et al. and Roussel et al. no effects on blood glucose were found after a 6-week intervention of supplementation with an aqueous cinnamon extract (500 mg/d), but were found after 12 weeks. Similarly, no beneficial effects were found in post-menopausal women with type 2 diabetes after only 6 weeks. Antioxidant effects were also not found to be significant after 6 weeks but were significant after 12 weeks in the study of Roussel et al. Whether differences in hormonal milieu affect the potential interaction between cinnamon supplementation and glucose control is unknown at this time. In all the human studies involving cinnamon, or aqueous extracts of cinnamon, there have been no reported adverse events and subjects with the poorest glycaemic control appear to benefit the most.

Model of cinnamon effects

A model of the potential diverse effects of cinnamon is depicted in Fig. 3. Cinnamon polyphenols (CP) affect multiple steps related to glucose and insulin function. CP activate insulin receptors by increasing their tyrosine phosphorylation activity and by decreasing phosphatase activity that inactivates the insulin receptor. CP also increase the amount of insulin receptor β and GLUT4 protein. CP increase glycogen synthase activity and glycogen accumulation, with decreased glycogen synthetase kinase-3 β activity. CP also increase the amount of the early-response anti-inflammatory protein, tristetraprolin. All these activities and other potential activities may eventually lead to more efficient glucose transport and utilization. In addition, CP-induced tristetraprolin accumulation may provide one of the molecular bases for the beneficial effects of cinnamon in improving the conditions of individuals with metabolic syndrome and insulin resistance by down regulating the synthesis of pro-inflammatory cytokines. It has also been reported that improvements in postprandial blood glucose response are related to gastric emptying rate but that the effects on postprandial glucose are greater than those on gastric emptying rate.

Conclusions

In summary, naturally-occurring insulin-potentiating compounds such as Cr and CP lead to increased insulin sensitivity characterized by improvements in characteristics of the metabolic syndrome and decreases in risk factors associated with diabetes and CVD. Individuals with metabolic syndrome, and the subsequent diabetes and CVD, have both decreased insulin sensitivity and decreased antioxidant status. Animal and human studies involving subjects with the metabolic syndrome, type 2 diabetes and polycystic ovary syndrome show beneficial effects of Cr, whole cinnamon and aqueous extracts of cinnamon on glucose, insulin, lipids and antioxidant status. There also may be effects on lean body mass and body composition, and inflammatory response. All these effects would lead to decreased risk factors associated with diabetes and CVD and improvements in the metabolic syndrome leading to decreased incidences of these diseases.

References


